Navigation Links
Combination therapy to treat breast cancer

The combination of two targeted drug therapies results in dramatic reduction in breast cancer cell growth in vitro, indicating a potentially powerful new approach to treating the condition.// The two drug agents – trastuzumab and ZD1839 were found to work synergistically to inhibit the action of two different growth factors receptors, HER2 and epidermal growth factor receptor (EGFR).

Previous research has shown that these growth factor receptors are involved in 20 and 70 per cent of breast cancers, respectively, and it has been suggested that they interact with one another to ensure cell proliferation and survival. Trastuzumab and ZD1839 have been specifically developed to target these receptors.

The agents were tested singly and then in combination. Individually, the drugs inhibited cell growth by between 30 and 55 per cent. Working together, trastuzumab and ZD1839 reduced cell proliferation by 70 per cent.

The findings suggest that simultaneous inhibition of the action of both growth factor receptors exerts a greater anti-tumour effect. The approach could be expanded to treat other types of cancer. Eventually, these combinations of drugs may be used with conventional cell-killing drugs. Alternatively, conventional chemotherapy may be used for short courses at times when the disease is more aggressive and targeted therapy used at other times.
'"/>




Page: 1

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination regime may work against prostate cancer
4. Smoking and Breast Cancer - A Deadly Combination
5. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
6. A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... Program will serve more than ... the U.S. Soccer Foundation announced today that they have awarded nine grants to ... the Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving ...
(Date:2/17/2017)... ... 17, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... – 22 in San Francisco. As part of the Tri-Conference expo, which is ... solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” , ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
(Date:2/16/2017)... Birmingham, AL (PRWEB) , ... February 17, 2017 ... ... asset protection assistance and financial planning services to families and entrepreneurs in the ... Bonnie, a local adoptive mother who needs assistance with her medically challenged son, ...
(Date:2/16/2017)... Angeles, CA (PRWEB) , ... February 16, 2017 , ... ... be confusing to the average patient. Parsa Mohebi, founder of Parsa Mohebi Hair Restoration, ... educate the public about the field of hair restoration, he recently expanded the information ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... --  Risperdal lawsuits involving gynecomastia (male breast growth) ... the atypical antipsychotic medication continue to move forward in ... Pleas, where the state,s Risperdal docket has been centralized ... posted on the Court,s website , the litigation ... 2017 at 11:00 a.m. (In Re: Risperdal Litigation, Case ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
Breaking Medicine Technology: